KRAS and hyperlipidemia: KRAS gene mutation (OR = 9.09, 95% CI: 5.50–15.75, p < 0.001), hyperlipidaemia (OR = 3.37, 95% CI: 1.35–7.86, p = 0.006), pancreatitis (OR = 29.97, 95% CI: 12.93–72.27, p < 0.001), and pancreatic cysts (OR = 17.29, 95% CI: 3.85–97.69, p < 0.001) were significantly correlated with an increased risk of pancreatic cancer.